280 related articles for article (PubMed ID: 1650833)
1. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
2. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
3. Antinociception and delta-1 opioid receptors in the rat spinal cord: studies with intrathecal 7-benzylidenenaltrexone.
Hammond DL; Stewart PE; Littell L
J Pharmacol Exp Ther; 1995 Sep; 274(3):1317-24. PubMed ID: 7562504
[TBL] [Abstract][Full Text] [Related]
4. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Adams JU; Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
[TBL] [Abstract][Full Text] [Related]
5. Evidence for delta opioid receptor subtypes in rat spinal cord: studies with intrathecal naltriben, cyclic[D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4]deltorphin.
Stewart PE; Hammond DL
J Pharmacol Exp Ther; 1993 Aug; 266(2):820-8. PubMed ID: 8394918
[TBL] [Abstract][Full Text] [Related]
6. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
7. Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion.
Stevens CW; Yaksh TL
J Pharmacol Exp Ther; 1989 Jul; 250(1):1-8. PubMed ID: 2526212
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
[TBL] [Abstract][Full Text] [Related]
9. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
11. Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors.
Russell RD; Leslie JB; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1987 Jan; 240(1):150-8. PubMed ID: 3027302
[TBL] [Abstract][Full Text] [Related]
12. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
Cahill CM; White TD; Sawynok J
J Pharmacol Exp Ther; 1995 Oct; 275(1):84-93. PubMed ID: 7562600
[TBL] [Abstract][Full Text] [Related]
13. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of opioid peptides selective for mu or delta receptors. II. Locomotor activity in nondependent and morphine-dependent rats.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):997-1003. PubMed ID: 3018231
[TBL] [Abstract][Full Text] [Related]
15. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
16. Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1995 Mar; 272(3):1135-40. PubMed ID: 7891326
[TBL] [Abstract][Full Text] [Related]
17. Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1993 Oct; 267(1):506-14. PubMed ID: 8229781
[TBL] [Abstract][Full Text] [Related]
18. The antinociception produced by intrathecal morphine, calcium, A23187, U50,488H, [D-Ala2, N-Me-Phe4, Gly-ol]enkephalin and [D-Pen2, D-Pen5]enkephalin after intrathecal administration of calcitonin gene-related peptide in mice.
Welch SP; Singha AK; Dewey WL
J Pharmacol Exp Ther; 1989 Oct; 251(1):1-8. PubMed ID: 2552070
[TBL] [Abstract][Full Text] [Related]
19. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman JS; Mulvaney SA; Mosberg HI; Porreca F
Brain Res; 1987 Sep; 420(1):100-8. PubMed ID: 2823970
[TBL] [Abstract][Full Text] [Related]
20. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
Baumhaker Y; Gafni M; Keren O; Sarne Y
Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
